Jennifer K. Moses Sells 750 Shares of G1 Therapeutics Inc (GTHX) Stock

G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $19.96, for a total value of $14,970.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of G1 Therapeutics Inc (GTHX) opened at $20.65 on Wednesday. G1 Therapeutics Inc has a 12-month low of $12.04 and a 12-month high of $28.67. The firm has a market capitalization of $585.33 and a P/E ratio of -9.60.

Hedge funds have recently made changes to their positions in the business. RA Capital Management LLC bought a new stake in G1 Therapeutics in the second quarter valued at approximately $46,813,000. Goldman Sachs Group Inc. bought a new stake in G1 Therapeutics in the second quarter valued at approximately $1,144,000. Laurion Capital Management LP bought a new stake in G1 Therapeutics in the second quarter valued at approximately $3,488,000. FMR LLC bought a new stake in G1 Therapeutics in the second quarter valued at approximately $34,093,000. Finally, Victory Capital Management Inc. bought a new stake in G1 Therapeutics in the second quarter valued at approximately $889,000. Hedge funds and other institutional investors own 43.25% of the company’s stock.

GTHX has been the subject of a number of recent research reports. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BTIG Research initiated coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 target price for the company. Finally, BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.40.

ILLEGAL ACTIVITY NOTICE: This article was published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.com-unik.info/2018/01/10/jennifer-k-moses-sells-750-shares-of-g1-therapeutics-inc-gthx-stock.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit